Ali Rassouli; Katayoun Kiani; Yalda Hosseizadeh Ardakani; Hamid Akbari Javar; Sakineh Khanamani Falahatipour
Volume 12, Issue 2 , June 2021, , Pages 253-257
Abstract
Sustained release drug formulations are frequently developed to reduce dosage frequency and to improve outcomes of drug therapy. This study evaluates the pharmacokinetic (PK) parameters of a novel injectable danofloxacin (DANO) formulation in comparison with a conventional product in an animal model. ...
Read More
Sustained release drug formulations are frequently developed to reduce dosage frequency and to improve outcomes of drug therapy. This study evaluates the pharmacokinetic (PK) parameters of a novel injectable danofloxacin (DANO) formulation in comparison with a conventional product in an animal model. A recently synthesized DANO formulation, prepared by incorporation of DANO-loaded mesoporous silica nanoparticles in liposomes and integration of liposomes in chitosan and β-glycerophosphate solution (lipogel) along with the conventional DANO product were injected subcutaneously (SC) in rabbits. Blood samples were collected at specific time points and DANO concentrations in plasma samples were measured. The PK parameters including maximum concentration (Cmax), time to reach Cmax (Tmax), area under the concentrationversustime curves (AUC), area under the first moment concentration-time curve (AUMC) and mean residence time (MRT) were studied by non-compartmental analyses. The values of MRT (156.00 ± 20.00 hr), AUC (15.30 ± 3.00 µg mL-1 perhr) and Tmax (4.70 ± 1.60 hr) for lipogel formulation were higher than those of the conventional product (8.50 ± 3.60 hr, 3.70 ± 2.00 µg mL-1 per hr and 0.80 ± 0.26 hr, respectively). However, Cmax values for lipogel formulation (0.41 ± 0.15 µg mL-1) were significantly lower than those of the conventional drug product (0.68 ± 0.09 µg mL-1). It was concluded that the novel DANO lipogel effectively slowed down the drug absorption and the incorporation of liposomes in hydrogel could be a useful approach to maintain the therapeutic drug level for a longer period; however, more studies are needed in this field.
Fish & Aquatic
Abdolhossein Jangaran Nejad; Rahim Peyghan; Hossein Najafzadeh Varzi; Ali Shahriyari
Volume 8, Issue 4 , December 2017, , Pages 327-331
Abstract
The aim of this study was to evaluate pharmacokinetic profiles of florfenicol after a single dose of intravenous (5.00 mg kg-1 body weight) and oral (40.00 mg kg-1 body weight) administrations in common carp (Cyprinus carpio). The residue depletion of florfenicol was also investigated after oral administration ...
Read More
The aim of this study was to evaluate pharmacokinetic profiles of florfenicol after a single dose of intravenous (5.00 mg kg-1 body weight) and oral (40.00 mg kg-1 body weight) administrations in common carp (Cyprinus carpio). The residue depletion of florfenicol was also investigated after oral administration (10.00 mg kg-1 body weight) and bath treatment (5.00 mg L-1) for 10 consecutive days. Pharmacokinetics of florfenicol in plasma after a single dose administration, at 10 time points (0.50, 1, 2, 4, 8, 12, 24, 72, 120 and 168 hr) and florfenicol concentrations in tissues (plasma, liver and muscle) at three time points (1, 7 and 14 days) after 10 consecutive days, were analyzed by high performance liquid chromatography. The peak concentration of florfenicol was 137.02 ng mL-1 and the time to reach peak concentration in plasma was two hr. The elimination half-lives, the volume of distribution at steady state and total body clearance were estimated as 21.40 hr, 0.30 and 0.03 L hr-1, respectively. After drug administration for 10 days, it's concentration in plasma and muscle in oral treatment was significantly more than bath treatment in all days. Drug concentrations in the liver after bath treatment were significantly higher for a shorter period than the concentration in the oral treatment, indicating that higher levels of florfenicol for a longer period can be achieved in the tissues after oral drug administration. According to pharmacokinetic results, florfenicol may be a suitable candidate for the treatment of common bacterial infections in common carp farming. The aim of this study was to evaluate pharmacokinetic profiles of florfenicol after a single dose of intravenous (5.00 mg kg-1 body weight) and oral (40.00 mg kg-1 body weight) administrations in common carp (Cyprinus carpio). The residue depletion of florfenicol was also investigated after oral administration (10.00 mg kg-1 body weight) and bath treatment (5.00 mg L-1) for 10 consecutive days. Pharmacokinetics of florfenicol in plasma after a single dose administration, at 10 time points (0.50, 1, 2, 4, 8, 12, 24, 72, 120 and 168 hr) and florfenicol concentrations in tissues (plasma, liver and muscle) at three time points (1, 7 and 14 days) after 10 consecutive days, were analyzed by high performance liquid chromatography. The peak concentration of florfenicol was 137.02 ng mL-1 and the time to reach peak concentration in plasma was two hr. The elimination half-lives, the volume of distribution at steady state and total body clearance were estimated as 21.40 hr, 0.30 and 0.03 L hr-1, respectively. After drug administration for 10 days, it's concentration in plasma and muscle in oral treatment was significantly more than bath treatment in all days. Drug concentrations in the liver after bath treatment were significantly higher for a shorter period than the concentration in the oral treatment, indicating that higher levels of florfenicol for a longer period can be achieved in the tissues after oral drug administration. According to pharmacokinetic results, florfenicol may be a suitable candidate for the treatment of common bacterial infections in common carp farming.